Indivior Pharmaceuticals (INDV) Current Assets (2021 - 2026)

Indivior Pharmaceuticals has reported Current Assets for 6 years, with the latest figure at $725.0 million in Q2 2026.

• On a quarterly basis, Current Assets fell 23.76% year-over-year to $725.0 million in Q2 2026; TTM through Jun 2026 was $725.0 million, a 23.76% decrease from a year earlier, with the FY2025 full-year figure at $652.0 million, down 21.16% from the prior year.
• Current Assets was $725.0 million for Q2 2026 at Indivior Pharmaceuticals, up from $667.0 million in the prior quarter.
• The five-year high for Current Assets was $1.3 billion in Q4 2022, with the low at $652.0 million in Q4 2025.
• Average Current Assets over 5 years is $904.8 million, with a median of $883.0 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Current Assets retreated 0.16% in 2023, then plunged 34.21% in 2024.
• Over 5 years, Current Assets stood at $1.3 billion in 2022, then retreated by 0.16% to $1.3 billion in 2023, then slumped by 34.21% to $827.0 million in 2024, then fell by 21.16% to $652.0 million in 2025, then climbed by 11.2% to $725.0 million in 2026.
• The last three Current Assets figures came in at $725.0 million (Q2 2026), $667.0 million (Q1 2026), and $652.0 million (Q4 2025), per Business Quant data.